Aminex Therapeutics, Inc. is a drug development company focused on advancing a novel immunotherapy for the treatment of cancer.
The Science
Polyamine Depletion Therapy
Aminex Therapeutics’ immuno-oncology approach significantly reduces the uptake and production of polyamines – molecules found in high concentrations in cancer cells and the tumor microenvironment and linked to immune system suppression. Reducing both sources of polyamines and, in turn, myeloid-derived suppressor cells in the tumor microenvironment, allows for activation of the innate immune system to attack solid tumors.
Learn More
Drug Candidate
AMXT 1501 + DFMO
Aminex Therapeutics’ immuno-oncology drug candidate is an oral, small molecule therapy. It is composed of AMXT 1501, the company’s patented polyamine uptake inhibitor, and DiFluoroMethylOrnithine (DFMO, eflornithine), an off-patent polyamine synthesis inhibitor. AMXT 1501 + DFMO works in conjunction to provide a synergistic immune system therapy applicable to a majority of solid tumor cancers.
Learn More
Latest News
Study Published in European Society for Medical Oncology (ESMO) Open Highlights Preliminary Clinical Activity of Aminex Therapeutics’ Dual Agent Immunotherapy Treatment Approach